Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410125 | 0.90 | PIK3CA (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4054314 | 0.87 | PIK3CA (0.55) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4053671 | 0.84 | PIK3CA (0.55) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4056586 | 0.83 | PIK3CA (0.57) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4060797 | 0.83 | PIK3CA (0.53) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4055900 | 0.83 | PIK3CA (0.59) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4063016 | 0.83 | SMPD3 (0.56) | PIK3CDPIK3CGPIK3CAPIK3CBBRD4 | |
| SCHEMBL4055698 | 0.82 | PIK3CA (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4060794 | 0.82 | PIK3CA (0.55) | PIK3CDPIK3CGPIK3CAPIK3CBFYN | |
| SCHEMBL4063804 | 0.81 | PIK3CA (0.55) | PIK3CDPIK3CGPIK3CAPIK3CBFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | claimed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | claimed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | PIK3CD 8/4885PIK3CG 13/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.